# **A. Frozen vs. Fine-Tuned: The Defining Methodological Difference DERIVED AFTER C1 IMPORTANT**

Every published result that beats or ties your numbers uses **full fine-tuning**, where all backbone weights are updated on the target dataset. Your results use **completely frozen backbones** with only the classification head trained.

This is not a limitation — it is the central scientific contribution. The literature on frozen transfer for retinal imaging is sparse, and the most relevant comparator tells a striking story:

> The Frontiers in Medicine benchmark (2026)[](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1815982/full) compared frozen encoders for referable-DR: on the development set (APTOS), all three encoders achieved near-identical binary AUC (0.980–0.985) — remarkably close to your 0.9852. But on external validation (MESSIDOR-2), **RETFound collapsed to 0.697** (drop 0.286). The authors concluded: _"Domain-specific pretraining did not guarantee domain-general frozen representations."_

Your work demonstrates the **opposite** pattern: domain-specific pretraining (RETFound native-392) actually achieves the **best** frozen-transfer result, and your bootstrap CIs confirm that this advantage is statistically significant vs. DINOv2-Base. This is a novel, evidence-backed finding that directly engages with — and partially refutes — a published conclusion. That is the kind of scientific dialogue that reviewers value highly.

# since dinov3 doesnt has almost no papers in it being used for retinal data through our specific methodology which i am planning to make like extraction of embeddings by frozen weights and then training a separate strong head (each head with different configuration in order to handle different type of tasks expertly) for every single task our results will become the benchmark for dinov3 on brset at least with our configuration. can we give our model architecture a name as well since it is first of its kind technically?


# PER TASK SINGLE TASK HEAD WORKING:

**The per-task single-task heads prediction.** This is the most substantive disagreement and Doc 56 is more empirically grounded than I was. I framed single-task heads as "completes the head axis, three possible findings, the third (mixed) is most likely." Doc 56 makes a sharper specific prediction: at your sample sizes, single-task heads will _underperform_ on dr_grade and on the sparse binaries (amd 22 positives, hypertensive_retinopathy 30 positives), because the binary tasks provide _auxiliary supervision_ that regularizes the shared trunk and benefits the sparse targets. Single-task strips that regularization and the sparse-positive tasks lose the implicit constraint that the features must also be useful for the dense tasks. This is a real mechanism in multi-task learning at small sample sizes and Doc 56's prediction is more accurate than my neutral framing. Your own intuition ("separating heads will help dr_grade") is likely wrong in the direction Doc 56 predicts. The experiment still has high value — it's the standard published-protocol comparison row, and it's the cleanest test of the negative-transfer hypothesis — but you should go in expecting MT > single-task on most cells with possible exceptions on the densest binary tasks (diabetes, drusen, other_ocular) where the shared trunk's auxiliary effect is smallest. Adopt Doc 56's prediction framing; mine was too neutral.

---

# DINOV3:   As of the visible literature I found, DINOv3 has been used on BRSET/mBRSET, but I did not find public evidence that DINOv3 ViT-L/16 has been evaluated on BRSET through our exact protocol: frozen embedding extraction + cached representations + MultiTaskHead / LinearProbeHead comparison across the broader BRSET multi-task label panel. 
## The real opportunity is BRSET → mBRSET transfer

This is the strongest point you made.

Their (Comparison of foundation models and transfer learning strategies for diabetic retinopathy classification) paper’s weakness is not internal BRSET discrimination. Their weakness is:

```
external validation on mBRSET dropped to AUROC 0.70–0.85calibration remained poormodels overestimated DR risk
```

That is where our pipeline can attack.

If we add DINOv3 ViT-L/16 and show any of the following, our contribution becomes stronger:

```
better BRSET → mBRSET transferbetter calibration on mBRSETlower ECE / Brier scoreless overestimation of DR riskbetter subgroup reliabilitybetter camera/device robustnessbetter OOD-aware rejection behaviorcompetitive AUROC at much lower compute
```

A slightly lower BRSET AUROC but stronger mBRSET transfer can be more publishable than another internal-BRSET number.
## 1. Has DINOv3 already been used on BRSET?

**Yes. At least two public traces exist.**

First, a 2026 medRxiv preprint titled **“Comparison of foundation models and transfer learning strategies for diabetic retinopathy classification”** evaluated **DINOv3, RETFound, and VisionFM** on **BRSET n=16,266** and **mBRSET n=5,164** for diabetic retinopathy classification. The searchable abstract says DINOv3 achieved the best BRSET discrimination under full fine-tuning, with AUROC up to **0.98 [95% CI: 0.97–0.99]**, but external validation on mBRSET dropped to **0.70–0.85**, and calibration remained poor. Their GitHub repo confirms the study focus: foundation models for **multi-class diabetic retinopathy classification**, with experiments for BRSET fine-tuning, external validation on mBRSET, and mBRSET transfer learning.

Second, PhysioNet released **“Embedding-Based Representations for BRSET and mBRSET”** in 2026, including precomputed embeddings from **DINOv3 ViT-S/16 and ViT-B/16**, plus ConvNeXt-Tiny/Base, for BRSET and mBRSET. The release states that all models were applied in **inference-only frozen mode** with standardized preprocessing, specifically to support rapid experimentation, fairness assessment, multimodal/lightweight AI systems, and cross-device studies.

So: **DINOv3 has already touched BRSET in both fine-tuning/classification research and frozen embedding release form.**

## 2. What exactly has DINOv3 already been used for?

DINOv3 itself was released by Meta in August 2025 as a large self-supervised vision foundation model. The original paper describes it as a generalist model trained without manual labels, using scaling, careful data preparation, **Gram anchoring**, and post-hoc resolution/model/text-alignment strategies; it claims strong dense features across many vision tasks. Meta’s release highlights its use for image classification, semantic segmentation, object tracking, object detection, relative depth, and satellite/environmental monitoring; they also emphasize that frozen DINOv3 features make lightweight adapters easier to train.

In **medical imaging**, DINOv3 has already been explored beyond retina. One benchmark paper, **“Does DINOv3 Set a New Medical Vision Standard?”**, evaluated it across **2D/3D classification, segmentation, and registration** across multiple medical modalities. The conclusion was balanced: DINOv3 is a strong baseline and can even outperform some medical-specific foundation models on several tasks, but it degrades in highly specialized domains like whole-slide pathology, electron microscopy, and PET; it also does not consistently obey scaling laws in medical imaging.

For **medical segmentation**, **MedDINOv3** adapted DINOv3 to CT/MRI segmentation using multi-scale token aggregation and domain-adaptive pretraining on **CT-3M**, a curated set of **3.87 million axial CT slices**. It reports state-of-the-art or comparable performance across four segmentation benchmarks.

For **medical registration**, another paper used a frozen DINOv3 encoder with test-time optimization for registration, reporting improved results on Abdomen MR-CT and ACDC cardiac MRI benchmarks.

In **retinal imaging**, DINOv3 has already been benchmarked against DINOv2 and RETFound. The paper **“Generalist versus Specialist Vision Foundation Models for Ocular Disease and Oculomics”** evaluates DINOv2/DINOv3 against RETFound-MAE and RETFound-DINOv2 on ocular disease detection and systemic prediction/oculomics tasks. It covers public ocular disease datasets such as APTOS-2019, IDRiD, Messidor-2, Papila, Glaucoma Fundus, and Kaggle Retina, plus systemic prediction of myocardial infarction, heart failure, and stroke. It found DINOv3 strong, but RETFound-DINOv2 still had the best average performance across tasks.

DINOv3 has also been used in **fundus image quality assessment**. EFIQA uses DINOv3 as the foundation-model backbone for dense/fundus quality maps and evaluates on datasets including **mBRSET**, MSHF, DRIMDB, and EyeQ; the implementation uses DINOv3 with **224×224** input and a lightweight adapter.

## 3. What has already been done specifically on BRSET?

Based on the currently visible literature/search results, BRSET already has:

|Work type|What was done|Why it matters for us|
|---|---|---|
|BRSET dataset paper|ConvNeXt V2-style baselines for DR, diabetes, sex prediction|Establishes BRSET as a benchmark; not DINOv3-centric.|
|DINOv3/RETFound/VisionFM DR study|DINOv3 used on BRSET and mBRSET for binary and three-class DR, with transfer-learning strategies and calibration evaluation|Directly blocks any “first DINOv3 on BRSET” claim.|
|PhysioNet embedding release|DINOv3 ViT-S/16 and ViT-B/16 frozen embeddings released for BRSET/mBRSET|Blocks “first frozen DINOv3 embedding extraction for BRSET” unless our extraction differs strongly.|
|BRSET/mBRSET GitHub study repo|Fine-tuning on BRSET, external validation on mBRSET, fine-tuning BRSET-trained models on mBRSET; metrics include AUROC, Brier, ECE, PDI, calibration slope/intercept|Their focus is DR discrimination/calibration, not full multi-condition pipeline.|

So the prior art is already quite real.


# **There is a PhysioNet release of DINOv3 BRSET and mBRSET embeddings.** A dataset titled "Embedding-Based Representations for BRSET and mBRSET v1.0.0" is on PhysioNet, dated March 2026. It contains precomputed image embeddings for both BRSET and mBRSET using DINOv3 ViT-S/16 (384-dim) and ViT-B/16 (768-dim), alongside ConvNeXt variants. The dataset explicitly states the use case: researchers can use these compact feature representations to train lightweight classifiers or regressors for tasks such as disease detection, diabetic retinopathy grading, image quality assessment, or demographic prediction. [PhysioNet](https://physionet.org/content/embedding-brset-mbrset/1.0.0/)[PhysioNet](https://physionet.org/content/embedding-brset-mbrset/1.0.0/)

This matters for your novelty claim. The release covers DINOv3 ViT-S/16 and ViT-B/16, **not** ViT-L/16, on BRSET _and_ mBRSET. That actually _helps_ your "DINOv3-Large on BRSET via our protocol" case rather than hurting it — they did Small and Base, not Large — but the headline framing "DINOv3 has not been applied to BRSET" needs to soften to "DINOv3-Large at our protocol has not been applied to BRSET, but DINOv3 ViT-S and ViT-B precomputed embeddings exist as a reference point." You should record this in F16 when it's created.

The more interesting implication: this PhysioNet release is positionable as a **comparator anchor**, not a threat. Your matrix's DINOv3-Large numbers can be discussed against the published DINOv3-S/B embedding-set numbers (if the PhysioNet release has companion paper benchmarks) for a scaling-within-DINOv3 finding. That's a free finding you get from this release existing.

There's a second thing worth noting that supports your novelty claim more than you knew: I also found that the Zhou et al. 2509.03421 paper showed DINOv3-Huge+ and DINOv3-Small+ both _underperformed_ DINOv3-Large on retinal tasks. So if DINOv3-L is the right scale within DINOv3 for retinal, and the PhysioNet release went with S and B (not L) for their BRSET/mBRSET embeddings, your DINOv3-Large insertion is the missing piece, not a duplicate.

**Part 2: your mBRSET transfer / calibration argument.**

This argument is largely correct and stronger than you stated, with a few small corrections.

The framing is right: the published BRSET DR work consistently shows internal AUROC in the 0.85–0.95 range, but the cross-population and cross-device drops are real and documented. Specifically the mBRSET paper itself benchmarks state-of-the-art deep models including ConvNeXt V2, Dino V2, and SwinV2 on mBRSET for clinical tasks but doesn't deeply analyze calibration, ECE, Brier, or subgroup reliability. Most BRSET DR papers don't either. So you're right that calibration on mBRSET is an under-attacked vector. [Nature](https://www.nature.com/articles/s41597-025-04627-3)

Your specific claims, audited one by one:

_"Better BRSET → mBRSET transfer"_ — defensible as a question to ask, not a claim to make. Whether DINOv3-L does better here is the experimental question. Frame it as an experiment that produces a finding either way, not as a predicted outcome.

_"Better calibration on mBRSET / lower ECE / Brier scores"_ — this is the strongest framing. Calibration is an under-reported metric across BRSET work and you have the reliability split (15%) already carved out to compute it. The novelty here is real: most foundation-model retinal papers report AUROC and stop, and ECE/Brier are a clear gap.

_"Less overestimation of DR risk"_ — this is the _specific clinical concern_ the mBRSET paper raised. Worth checking whether DINOv3-Large's calibration profile is systematically different from ConvNeXt V2 / DINOv2 in either direction. This is a one-sentence-stateable finding.

_"Better subgroup reliability"_ — depends on whether DINOv3-L's representation interacts differently with the BRSET sex/age/camera subgroups than DINOv2-L does. Open question, valuable experiment.

_"Better camera/device robustness"_ — this is the Canon-vs-Nikon-within-BRSET question (clean device-effect natural experiment) and the BRSET→mBRSET question (full acquisition-modality shift). Both are real, both are unattacked, and DINOv3's Gram-anchoring and 1.7B-image pretraining may genuinely help.

_"Better OOD-aware rejection behavior"_ — interesting framing but probably out of scope for the initial paper. Defer to a future extension; mentioning it in the framing doc as a potential future direction is fine.

_"Competitive AUROC at much lower compute"_ — true relative to DINOv2-Giant (which Zhou et al. confirms), but DINOv3-L at 300M params is the same scale as DINOv2-L (300M), so the "lower compute" claim only holds vs Giant or 7B variants, not vs DINOv2-L. Word this carefully: "DINOv3-Large achieves DINOv3's full-suite performance at 300M params, avoiding the compute cost of Huge+ or 7B variants."

**The strongest framing — your own conclusion — is correct:** "A slightly lower BRSET AUROC but stronger mBRSET transfer can be more publishable than another internal-BRSET number." That's exactly the right scientific instinct. The paper's contribution isn't "we got the highest BRSET AUROC"; it's "we built a framework that interrogates frozen-foundation-model behavior under realistic distribution shift, and DINOv3-Large is the natural-image-pretrained next-generation point that completes the comparison axis."